There is no commercial support for this activity.

About the speakers

Scott Aaronson, MD, is the Chief Science Officer for the Institute for Advanced Diagnostics and Therapeutics at Sheppard Pratt in Baltimore, Maryland. He is an Adjunct Professor in the Department of Psychiatry at the University of Maryland School of Medicine. Dr Aaronson specializes in treatment-resistant affective disorders. His work focuses on the development of various novel paradigms including neurostimulation and psychedelic assisted psychotherapy to treat severe mood disorders. He has been an international leader in the development of vagus nerve stimulation and transcranial magnetic stimulation. He is a member of the Board of Directors of the American Society for Clinical Psychopharmacology. Dr Aaronson earned his MD with honors from Harvard Medical School and completed a residency in psychiatry at McLean Hospital.  He is a Distinguished Life Fellow of the American Psychiatric Association and a Fellow of the American College of Psychiatrists.

Monica Rettenmier, MD is board certified in both child/adolescent and adult psychiatry.  She is the service chief of the Electroconvulsive Therapy department at Sheppard Pratt.  Her areas of interest include primary mood disorders, including treatment resistant unipolar and bipolar depression, as well as anxiety disorders, in both adult and pediatric populations. Dr. Rettenmier is trained in the Neuromodulation areas of electroconvulsive therapy (ECT) and transcranial magnetic stimulation (TMS).  She also works as a staff child/adolescent psychiatrist in the Telehealth Outpatient Services of Sheppard Pratt.  Before this role, she worked as a staff psychiatrist in the Child/Adolescent Partial Hospitalization Program of Sheppard Pratt, providing care to children and adolescents in an acute care setting.

Patricia Carlson, MD is a board-certified adult psychiatrist and is service chief of the TMS program for Sheppard Pratt.  Her areas of interest include mood disorders, including treatment resistant depression, as well as generalized anxiety and obsessive-compulsive disorder.  Dr. Carlson is on staff with the Department of Clinical Research at Sheppard Pratt, where she works with research protocols related to treatment resistant depression.  She is trained in multiple forms of Neurostimulation including transcranial magnetic stimulation (TMS), electroconvulsive therapy (ECT) and VNS protocols.  She is trained in transference focused psychotherapy (TFP), dialectical behavior therapy (DBT), and exposure response prevention therapy. She has taught courses in shame resilience and other topics related to common human sufferings such as loss and trauma. 

Disclosure Statements

Sheppard Pratt holds the standard that its continuing medical education programs should be free of commercial bias and conflict of interest. In accord with Sheppard Pratt's Disclosure Policy, as well as standards of the Accreditation Council for Continuing Medical Education (ACCME) and the American Medical Association (AMA), all planners, reviewers, speakers and persons in control of content have been asked to disclose any relationship he /she has with any entity producing, marketing, selling, re-selling, or distributing health care goods or services consumed by, or used on, patients, during the past 24 months. All planners, reviewers and speakers have also been asked to disclose any payments accepted for this lecture from any entity besides Sheppard Pratt Health System, and if there will be discussion of any products, services or off-label uses of product(s) during this presentation.

Scott T. Aaronson, MD, reports having the following relationships with financial interest: Compass Pathways- researcher, consultant; Neuronetics- researcher, consultant; LivaNova- researcher, consultant; Janssen- consultant; Sage Therapeutics- consultant; and Genomind- consultant. He will be discussing treatment utilizing Esketamine, TMS, and ECT as well as discussing off-label uses regarding research into psychedelics for multiple psychiatric indications. The content of his presentation was reviewed to find and mitigate any conflicts of interest to ensure that the information presented is balanced and evidence-based and contains no logos, brand-names, or advertisements. He will not discuss any products or services during this presentation, except in their generic form. This presentation will focus on research.

Monica N. Rettenmier, MD, reports having no financial interest, arrangement or affiliation with any entity producing, marketing, selling, re-selling, or distributing health care goods or services consumed by, or used on, patients, during the past 24 months. She will be discussing ECT and its service options in this presentation. All relationships have been mitigated through review. 

Patricia Carlson MD, reports that she has no relationships with any entity producing, marketing, selling, re-selling, or distributing health care goods or services consumed by, or used on, patients during the past 24 months. She will not discuss any products, services, or off-label uses in this presentation. All relationships have been mitigated through review.

Event Planners/Reviewers Disclosures: The following event planners and/or reviewers are reported as having no financial interest, arrangement or affiliation with any entity producing, marketing, selling, re-selling, or distributing health care goods or services consumed by, or used on, patients, during the past 24 months: Todd Peters, MD, Elizabeth Ryznar, MD, MSc, Louis J. Marino, Devi Bhuyan, PsyD, Faith Dickerson, PhD, Carrie Etheridge, LCSW-C, April Sobiech, LCSW-C, Latia Suite, LCSW-C, Rachel Smolowitz, PhD, Tom Flis, LCPC, Stacey Garnett, RN, MSN, Stephanie M. Robinson, MSN, RN, Lisa E. Seldon, DNP, MSA, RN, NEA-BC, Lisa Illum, MLIS, MEd, and Jennifer Tornabene.